Evoqua Water Technologies, a Downtown-based water treatment company, has had an interesting view of the pandemic. With its hands in so many industries, things like oil and gas shutdowns — as well as COVID-related pool closures — have been drags on revenue.
On the other hand, demand for purified water in the health care industry, including pharmaceutical manufacturing and biotech operations, have added buoyancy, helping Evoqua report $347.8 million in revenue for the three months ending June 30, down only 3.5% from a year prior.
The company reported net income of $21.3 million, or 18 cents per share, compared to $4.1 million, or 3 cents per share, during the same quarter last year.

Company representatives said a $9.7 million hit to revenue came from the sale of a line of membrane bioreactors, which are used to filter wastewater. The line was sold to DuPont on Dec. 31.
Evoqua’s purification equipment, which creates highly purified (or “ultrapure”) water, was in demand in the microelectronics industry. The water is used as a solvent for removing tiny contaminants from dense microchips, CEO Don Keating said in Tuesday’s earnings call.
Heading into next quarter, Mr. Keating said the company’s market in health care, pharmaceuticals and biotechnology remain strong and are expected to grow. Highly purified water also plays a key role in pharmaceutical manufacturing and laboratory testing.
“The need for ultrapure water is in high demand, and we’re prioritizing our service capabilities to these essential markets,” he said.
Evoqua’s biggest COVID-19-related hit came in its service sector, particularly for oil and gas refinement, Mr. Keating said. Recent volatility in the global oil market created delays and decreased demand, and service revenue declined $8.8 million from the year prior.
Delayed and canceled pool openings cut into revenue in the domestic aquatics sector, where it provides water filtration products.
Profitability was also hit by $2.8 million in operational variances from lower service volumes and implementing enhanced safety protocols for COVID-19.
Ethan Simmons: 412-263-1548; esimmons@post-gazette.com
This story was originally published with images that are no longer available.






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.